Core Viewpoint - U.S. health insurers' shares surged following reports of a potential two-year extension of Affordable Care Act (ACA) premium subsidies, which would alleviate concerns over premium increases and enrollment declines [1][3]. Group 1: Company Reactions - Centene's shares increased by approximately 7%, Molina Healthcare's shares rose around 4%, and Elevance Health's shares climbed more than 2% in early trading [1]. - Hospital operators also saw positive movements, with HCA Healthcare shares rising by 3.2%, Universal Health Services up nearly 2%, and Tenet Healthcare jumping 6% [4]. Group 2: Market Sentiment - The anticipated two-year extension is viewed as a "better than feared" scenario for health insurers, providing relief after uncertainty surrounding ACA subsidies [2]. - Investors had been cautious due to the potential expiration of pandemic-era enhanced tax credits, but public support for extending these credits remains strong, with about three-quarters of U.S. adults favoring renewal [6]. Group 3: Industry Implications - The proposed policy framework is expected to ease risks associated with sharp premium increases and potential enrollment declines in 2026, thereby improving healthcare affordability [3]. - Analysts suggest that the proposals, although still in early stages, would be favorable for healthcare services, including hospitals and managed care businesses [4].

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH). Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/ ...

Core Insights - Molina Healthcare, Inc. is a significant player in the U.S. managed care sector, focusing on health insurance for individuals and families under government programs, with a market cap of $7.7 billion [1] Stock Performance - Molina shares have experienced a significant decline of 52.2% over the past year, contrasting sharply with the S&P 500 Index, which gained 11% during the same period [2] - In the last six months, Molina's stock plummeted 55.7%, while the S&P 500 Index rose by 13% [2] Industry Comparison - Within the healthcare sector, Molina's performance has lagged behind the SPDR S&P Health Care Services ETF, which increased by 12.5% over the past year and 8.6% over the past six months [3] Financial Results - For Q3 2025, Molina reported a revenue increase of 11% year over year, reaching $11.5 billion, but adjusted EPS fell dramatically by 69.4% to $1.84 [4] - The consolidated medical care ratio rose to 92.6%, primarily due to higher costs in the ACA segment [4] - Membership grew to 5.6 million, but this was insufficient to alleviate profit concerns [4] Earnings Guidance - Molina has revised its full-year adjusted EPS guidance down to approximately $14, a significant drop from earlier expectations of around $19, marking the third guidance reduction of the year [4] - Analysts project a 38.4% year-over-year decline in EPS for the current fiscal year, estimating it at $13.95 on a diluted basis [5] Analyst Sentiment - The consensus rating for Molina's stock is "Hold," with 18 analysts providing recommendations: 3 suggest "Strong Buy," 12 recommend "Hold," 1 has a "Moderate Sell," and 2 advise a "Strong Sell" [6]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit claims that Molina failed to disclose several material adverse facts regarding its financial health, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in recent years [4]. Group 3: Case Specifics - The lawsuit alleges that Molina's management misrepresented the company's medical cost trend assumptions and financial guidance for fiscal year 2025, leading to investor damages when the true information was revealed [5].

Group 1 - The article discusses a class action lawsuit on behalf of purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) for the period between February 5, 2025, and July 23, 2025 [1] - Molina Healthcare is identified as a health insurance company [1] - The Rosen Law Firm is investigating allegations related to the class action lawsuit [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal rights [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific issues cited include a dislocation between premium rates and medical costs, dependence on low utilization of various health services, and the likelihood of cutting financial guidance for fiscal year 2025 [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [6]. - The company cut its full-year adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50 [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [8]. - The new guidance indicated a 13.6% cut to earnings per share, with full-year GAAP net income guidance reduced by 27% to $912 million [8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant reduction in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Molina Healthcare failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the company's financial guidance for fiscal year 2025 [5]. - It is claimed that these undisclosed facts led to misleading statements about Molina's business operations and prospects, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. for alleged violations of federal securities laws, encouraging affected investors to participate in a class action lawsuit [2][5]. Summary by Sections Legal Action - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may have the opportunity to lead a class action lawsuit against the company [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action is December 2, 2025 [2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding: 1. Material adverse facts about the company's medical cost trend assumptions [5]. 2. A dislocation between premium rates and medical cost trends [5]. 3. Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. 4. Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. 5. Misleading positive statements about the company's business and operations [5]. Financial Performance - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50 [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [8]. - The new guidance for full-year 2025 adjusted earnings was set at no less than $19.00 per diluted share, reflecting a 13.6% cut from previous guidance [8]. - Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share following this announcement [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [5].